A Phase 4 interventional study of Apixaban and Standard of Care in Venous Thromboembolism, sponsored by Bristol-Myers Squibb. Completed at 128 sites in 13 countries. Open to participants aged 0 Days to 17 Years. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.
Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 4, and was the 5th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
University of Vermont · Sites in United States
Ages 18+
Kiranya Arnold · Sites in United States
Ages 18–89
Rushad Patell · Sites in United States
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 0 Days to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 6 · Phase 4 14
First in 2011; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 229 is close to the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 100 across the 37 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Venous Thromboembolism by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 12 finished, 1 (8%) have results posted.
Among the 12 studies in Venous Thromboembolism by Bristol-Myers Squibb, this one is one of 3 that started in 2015, is the only one in phase 4, and was the 3rd registered.
Bristol-Myers Squibb’s Venous Thromboembolism studies by the year they started, since 2010.
7 of the studies testing apixaban in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT05683808University of Vermont Medical CenterVenous Thromboembolism Prevention in Outpatients With Glioma | 2026-12-30 |
| NCT07869615Military Hospital of TunisComparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty | 2027-04-15 |
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 37 studies testing apixaban in Venous Thromboembolism, from their registry updates:
Among Bristol-Myers Squibb’s 12 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects between birth to \<18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;\<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;\<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;\<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;\<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;\< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;\<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;\<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
Drug: Apixaban · Drug: Standard of Care
Tablet or Solution
Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding
Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite.
Time frame: From first dose (Day 1) up to 114 days
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality
Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.
Time frame: From first dose (Day 1) up to 114 days
Percentage of Participants Who Died
Death due to any cause was assessed. 95% CI was calculated using the Agresti-Coull method.
Time frame: From first dose (Day 1) up to 114 days
Percentage of Participants With Venous Thromboembolism (VTE)-Related Mortality
Participants were assessed for death due to Venous Thromboembolism (VTE).
Time frame: From first dose (Day 1) up to 114 days
Number of Participants With Index Venous Thromboembolism (VTE) Status
Index VTE status was defined as the last image obtained during the Main treatment phase for each participant's comparison to baseline imaging. Index VTE status was classified as Recurrence-contiguous; Recurrence-new; Unchanged; Regression; Resolution; Indeterminate/Nondiagnostic. Participants could have multiple concomitant index events. Regression was defined as (ie, unequivocal decrease \[\>50%\] of the total volume/mass of the thrombus compared to the index event)
Time frame: From first dose (Day 1) up to 91 days
Percentage of Participants With Stroke
Participants were assessed for incidence of stroke.
Time frame: From first dose (Day 1) up to 114 days
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE)
Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.
Time frame: From first dose (Day 1) up to 114 days
Number of Participants With New Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE)
Participants were assessed for incidence of Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE).
Time frame: From first dose (Day 1) up to 114 days
Percentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE)
Other VTE included events such as cerebral sinovenous thrombosis, renal vein thrombosis, portal vein thrombosis, catheter-related VTE, and splanchnic thrombosis. If VTE event type was blank, it was included in the Other VTE. 95% CI was from the Agresti-Coull method.
Time frame: From first dose (Day 1) up to 114 days
Number of Participants With Clinically Relevant Non-Major (CRNM) Bleeding, Major Bleeding and Minor Bleeding
Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite. Minor bleeding was defined as any overt or macroscopic evidence of bleeding that does not fulfill the above criteria for either major bleeding or clinically relevant, non-major bleeding.
Time frame: From first dose (Day 1) up to 114 days
Blood Concentration of Apixaban (ng/mL)
Blood samples were collected to assess the apixaban concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 1.0 ng/mL for plasma samples, and 0.5 ng/mL for dried blood samples.
Time frame: 3 hour (H), 12 H, 24 H at Day 3; pre and post dose at Day 14 and Day 42
Concentration of Plasma Anti-Factor Xa (ng/mL)
Blood samples were collected to assess the Anti-Factor Xa concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 35.0 ng/mL.
Time frame: Pre and post dose at Day 14 and Day 42
| Milestone | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Started | 155 | 74 |
| Completed | 138 | 65 |
| Not completed | 17 | 9 |
| Withdrew: Adverse event | 7 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 4 |
| Withdrew: No longer meets eligibility criteria | 0 | 1 |
| Withdrew: Other reasons | 4 | 2 |
| Withdrew: Entrance criteria | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Started | 53 | 0 |
| Completed | 50 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 |
Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding | 1.3 (0.1 to 5.0) | 1.4 (0.0 to 8.1) |
Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality | 2.6 (0.8 to 6.7) | 2.7 (0.2 to 9.9) |
Death due to any cause was assessed. 95% CI was calculated using the Agresti-Coull method.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants Who Died | 1.3 (0.1 to 4.9) | 1.4 (0.0 to 8.0) |
Participants were assessed for death due to Venous Thromboembolism (VTE).
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Venous Thromboembolism (VTE)-Related Mortality | 0 | 0 |
Index VTE status was defined as the last image obtained during the Main treatment phase for each participant's comparison to baseline imaging. Index VTE status was classified as Recurrence-contiguous; Recurrence-new; Unchanged; Regression; Resolution; Indeterminate/Nondiagnostic. Participants could have multiple concomitant index events. Regression was defined as (ie, unequivocal decrease \[\>50%\] of the total volume/mass of the thrombus compared to the index event)
| Participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Recurrence-contiguous | 2 | 0 |
| Recurrence-new | 0 | 0 |
| Unchanged | 8 | 6 |
| Regression | 25 | 11 |
| Resolution | 77 | 36 |
| Indeterminate/Nondiagnostic | 15 | 7 |
| Missing Follow-up Imaging, therefore cannot compare to baseline | 5 | 8 |
| Imaging not completed within the specified time period | 6 | 1 |
Participants were assessed for incidence of stroke.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Stroke | 0 | 0 |
Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) | 2.6 (0.8 to 6.7) | 2.7 (0.2 to 9.9) |
Participants were assessed for incidence of Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE).
| Participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| New Symptomatic or Asymptomatic DVT | 1 | 1 |
| New Symptomatic or Asymptomatic PE | 0 | 0 |
Other VTE included events such as cerebral sinovenous thrombosis, renal vein thrombosis, portal vein thrombosis, catheter-related VTE, and splanchnic thrombosis. If VTE event type was blank, it was included in the Other VTE. 95% CI was from the Agresti-Coull method.
| percentage of participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Percentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE) | 1.9 (0.4 to 5.8) | 1.4 (0.0 to 8.0) |
Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite. Minor bleeding was defined as any overt or macroscopic evidence of bleeding that does not fulfill the above criteria for either major bleeding or clinically relevant, non-major bleeding.
| Participants | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Major Bleeding | 0 | 0 |
| Clinically Relevant Non-major Bleeding | 2 | 1 |
| Minor Bleeding | 54 | 21 |
Blood samples were collected to assess the apixaban concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 1.0 ng/mL for plasma samples, and 0.5 ng/mL for dried blood samples.
| nanogram per millilitre (ng/mL) | Participants Between Age 12 to < 18 Years | Participants Between Age 2 - < 12 Years | Participants With Age 28 Days - < 2 Years | Participants in Age Group-Birth - ≤ 27 Days |
|---|---|---|---|---|
| Hour 3 at Day 1 | — | — | — | 30.7 ± 12.9 |
| Hour 12 at Day 1 | — | — | — | 13.9 ± 5.70 |
| Hour 24 at Day 1 | — | — | — | 23.3 ± 10.1 |
| Pre-dose at Day 14 | 61.1 ± 53.7 | 72.7 ± 42.5 | 56.4 ± 65.6 | 48.3 ± 23.0 |
| Post-dose at Day 14 | 152 ± 80.2 | 189 ± 61.0 | 203 ± 118 | 119 ± 45.7 |
| Pre-dose at Day 42 | 54.5 ± 33.7 | 67.9 ± 33.8 | 123 ± 123 | 50.2 ± 34.1 |
| Post-Dose at Day 42 | 151 ± 79.1 | 212 ± 89.8 | 143 ± 88.0 | 109 ± 56.0 |
Blood samples were collected to assess the Anti-Factor Xa concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 35.0 ng/mL.
| nanogram per millilitre (ng/mL) | Participants Between Age 12 to < 18 Years | Participants Between Age 2 - < 12 Years | Participants With Age 28 Days - < 2 Years | Participants in Age Group-Birth - ≤ 27 Days |
|---|---|---|---|---|
| Pre-dose at Day 14 | 72.7 ± 60.4 | 82.7 ± 41.3 | 74.7 ± 69.7 | 48.0 ± 1.00 |
| Post-dose at Day 14 | 147 ± 83.5 | 202 ± 75.8 | 190 ± 105 | 127 ± 4.04 |
| Pre-dose at Day 42 | 63.9 ± 27.4 | 75.3 ± 31.0 | 53.5 ± 13.4 | — |
| Post-Dose at Day 42 | 153 ± 84.9 | 220 ± 98.4 | 156 ± 92.2 | 101 ± NA |
Collected over Non-Serious adverse events were collected from first dose Day 1 up to end of treatment visit (Day 168) plus 35 days i.e., up to 203 days. Serious Adverse Events and all cause mortality was collected from Screening (Day -7) to end of treatment visit (Day 168) plus 35 days i.e., up to 210 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Receiving Apixaban | 2/155 (1.3%) | 40/152 (26.3%) | 132/152 (86.8%) |
| Participants Treated With Standard of Care | 1/74 (1.4%) | 17/73 (23.3%) | 59/73 (80.8%) |
| Event | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/152 | 2/73 |
| PyrexiaGeneral disorders | 4/152 | 1/73 |
| Alanine aminotransferase increasedInvestigations | 3/152 | 0/73 |
| Cardio-respiratory arrestCardiac disorders | 0/152 | 1/73 |
| Chest painGeneral disorders | 0/152 | 1/73 |
| Non-cardiac chest painGeneral disorders | 1/152 | 1/73 |
| Peripheral swellingGeneral disorders | 0/152 | 1/73 |
| Escherichia pyelonephritisInfections and infestations | 0/152 | 1/73 |
| PyomyositisInfections and infestations | 0/152 | 1/73 |
| VaricellaInfections and infestations | 0/152 | 1/73 |
| Event | Participants Receiving Apixaban | Participants Treated With Standard of Care |
|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 27/152 | 14/73 |
| HeadacheNervous system disorders | 27/152 | 10/73 |
| Injection site bruisingGeneral disorders | 1/152 | 12/73 |
| VomitingGastrointestinal disorders | 22/152 | 4/73 |
| ContusionInjury, poisoning and procedural complications | 14/152 | 10/73 |
| AnaemiaBlood and lymphatic system disorders | 5/152 | 8/73 |
| Heavy menstrual bleedingReproductive system and breast disorders | 16/152 | 3/73 |
| DiarrhoeaGastrointestinal disorders | 15/152 | 6/73 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 15/152 | 6/73 |
| PyrexiaGeneral disorders | 11/152 | 7/73 |
| Age, Continuous(years) | Participants Receiving Apixaban | Participants Treated With Standard of Care | Total |
|---|---|---|---|
| Mean | 11.10 ± 6.51 | 11.68 ± 6.02 | 11.29 ± 6.35 |
| Sex: Female, Male(Participants) | Participants Receiving Apixaban | Participants Treated With Standard of Care | Total |
|---|---|---|---|
| Female | 85 | 43 | 128 |
| Male | 70 | 31 | 101 |
| Ethnicity (NIH/OMB)(Participants) | Participants Receiving Apixaban | Participants Treated With Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 13 | 25 |
| Not Hispanic or Latino | 143 | 61 | 204 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Participants Receiving Apixaban | Participants Treated With Standard of Care | Total |
|---|---|---|---|
| White | 120 | 55 | 175 |
| Black | 22 | 9 | 31 |
| Asian | 5 | 4 | 9 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 6 | 5 | 11 |
| Multiracial | 1 | 1 | 2 |
Showing the first 100 of 128 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2015 to primary completion in Apr 2024, 101 months.
Results were first posted in Oct 2024, 5 months after primary completion.
Of 34 phase 4 interventional studies under Venous Thromboembolism, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 88. This study's 101 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban